Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood test may reveal early if lung cancer therapy works

NCT ID NCT03926260

Knowledge-focused Sponsor: Centre Hospitalier Departemental Vendee Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 100 people with advanced non-small cell lung cancer to see if changes in tumor DNA in the blood (ctDNA) can predict how well treatment is working. Researchers took blood samples before treatment, at 3 weeks, and at 9 weeks. The goal was to see if a rise or fall in ctDNA levels matches tumor shrinkage or growth on scans. This is an observational pilot study, not a test of a new drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test to quickly tell if lung cancer treatment is working, helping doctors adjust therapy earlier.
What could go wrong
This is a small, early pilot study (100 people) that only observes DNA changes—it does not test a new treatment. The findings may not apply to all patients or lead to a reliable test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Jun 2019

Finished

May 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Metastatic or locally advanced non-small cell lung cancer (stage III or IV) * At least one measurable target according to RECIST criteria * Identification of at least one molecular alteration in the tissue sample analyzed in the framework of patient management * Performance Status 0 to 2 * Affiliated to a social security system * Patient who can be followed under the protocol * Patient agreed to participate in the study and gave his/her express consent Exclusion Criteria: * Minor * Small cell or mixed bronchial cancer * Radiotherapy (except radiotherapy for antalgic purposes) during the last 7 days * Patient who has already started a first line of treatment * Patient already included in an interventional research protocol that may have an impact on the results of the ELUCID study * History of cancer (with the exception of non-melanoma skin, cervical cancer in situ, adequately treated) with sign of illness during the last 5 years * Patient which, does present a substantial risk of recurrence. * Major under guardianship, curators or deprived of liberty * Pregnant or lactating woman, or of childbearing age without effective contraception * Not affiliated to a social security system * Inability to understand the protocol and / or to give express consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic non-small cell lung cancer

Contacts and locations

Locations

  • Jaafar BENNOUNA

    Nantes, 44000, France

  • Marie MARCQ

    La Roche-sur-Yon, 85000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.